Marco Sciveres

ORCID: 0000-0002-4092-9071
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Liver Diseases and Immunity
  • Pediatric Hepatobiliary Diseases and Treatments
  • Liver Disease Diagnosis and Treatment
  • Liver Disease and Transplantation
  • Hepatitis B Virus Studies
  • Gallbladder and Bile Duct Disorders
  • Celiac Disease Research and Management
  • Organ Transplantation Techniques and Outcomes
  • Drug Transport and Resistance Mechanisms
  • Renal Transplantation Outcomes and Treatments
  • Congenital Anomalies and Fetal Surgery
  • Systemic Lupus Erythematosus Research
  • Hepatitis Viruses Studies and Epidemiology
  • Neonatal Health and Biochemistry
  • Pancreatitis Pathology and Treatment
  • Cytomegalovirus and herpesvirus research
  • Microscopic Colitis
  • Renal Diseases and Glomerulopathies
  • Gastrointestinal disorders and treatments
  • Intestinal Malrotation and Obstruction Disorders
  • Blood groups and transfusion
  • IgG4-Related and Inflammatory Diseases
  • Biliary and Gastrointestinal Fistulas
  • Immunodeficiency and Autoimmune Disorders
  • Blood Coagulation and Thrombosis Mechanisms

Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione
2015-2025

University of Palermo
2022-2025

Istituti di Ricovero e Cura a Carattere Scientifico
2016-2025

Bambino Gesù Children's Hospital
2024-2025

University of Pittsburgh
2008-2014

Ospedale Vincenzo Cervello
2011

University of Pisa
2004-2011

Inonu University
2010

Atatürk University
2010

Erzurum Technical University
2010

Background & AimsPFIC2 is caused by mutations in ABCB11 encoding BSEP. In most cases affected children need liver transplantation that thought to be curative. We report on two patients who developed recurrent normal GGT cholestasis mimicking primary BSEP disease, after transplantation.MethodsPFIC2 diagnosis was made infancy both absence of canalicular immunodetection and mutation identification. Liver performed at age 9 (patient 1) 2.8 2) years without major complications. Cholestasis with...

10.1016/j.jhep.2010.05.025 article EN cc-by-nc-nd Journal of Hepatology 2010-07-30

The human EBV-transformed lymphoblastoid cell line (LCL), obtained by infecting peripheral blood monocular cells with Epstein–Barr Virus, has been extensively used for genetic, pharmacogenomic, and immunologic studies. Recently, the role of exosomes also indicated as crucial in crosstalk between EBV host microenvironment. Because that LCL exosomal cargo might play maintaining persistent infection, since little is known regarding non-coding RNAs LCL, aim our work was comprehensive...

10.1016/j.canlet.2016.12.003 article EN cc-by-nc-nd Cancer Letters 2016-12-10

The current pandemic SARS-CoV-2 has required an unusual allocation of resources that can negatively impact chronically ill patients and high-complexity procedures. Across the European Reference Network on Pediatric Transplantation (ERN TransplantChild), we conducted a survey to investigate COVID-19 outbreak pediatric transplant activity healthcare practices in both solid organ transplantation (SOT) hematopoietic stem cell (HSCT). replies 30 professionals from 18 centers Europe were...

10.1111/ctr.14063 article EN Clinical Transplantation 2020-08-12

Celiac disease (CD) is common in patients with autoimmune liver (AILD); however, the long-term response to treatment of AILDs coexistent CD has not been explored detail. The aim present study was analyze features and immunosuppressive children hepatitis (AIH) associated CD.Retrospective prospective evaluation followed at a single center.Among 79 AIH, 15 (19%) had (9 type 1, 3 2, seronegative). In group AIH CD, female sex significantly more represented than alone; also, former group,...

10.1097/mpg.0b013e31828b1dfa article EN Journal of Pediatric Gastroenterology and Nutrition 2013-02-12

Abstract Background and rationale Progressive familial intrahepatic cholestasis (PFIC) associated with myosin 5B deficiency is a rare liver disease characterised by elevated serum bile acids (sBAs) severe pruritus. The objective of this study was to evaluate treatment the ileal acid transporter inhibitor odevixibat in affected children. Methods This retrospective analysis five children diagnosis PFIC pruritus refractory rifampicin ursodeoxycholic acid, starting (37.2–120 µg/kg.day) between...

10.1186/s13023-025-03728-x article EN cc-by Orphanet Journal of Rare Diseases 2025-05-12

ABSTRACT As pediatric liver transplantation comes of age, experts gathered to discuss current paradigms and define gaps in knowledge warranting research further improve patient graft outcomes. Identified areas ripe for collaborative include understanding the molecular cellular mechanisms tolerance role donor‐specific antibodies, considering ways expand donor pool, minimizing long‐term side effects immunosuppression, fine‐tuning surgical techniques minimize biliary vascular complications.

10.1097/mpg.0000000000001564 article EN Journal of Pediatric Gastroenterology and Nutrition 2017-03-17

Abstract Background and Aims In paediatrics, porto‐sinusoidal vascular disease (PSVD) is relatively unknown probably underdiagnosed. We aimed to describe clinical phenotypes, histology outcome of children diagnosed with PSVD. Methods Retrospective multicentre study Diagnosis PSVD was based on histopathology reports; liver specimens were re‐evaluated by two expert pathologists. Results Sixty (M/F = 36/26, median age 6.6 years, range 3.3–10.6), from 7 centres, included. Thirty‐six presented...

10.1111/liv.15603 article EN Liver International 2023-05-08

Conventional treatment for autoimmune hepatitis results in a significant percentage of failures and several, poorly tolerated, side-effects. Therapy cholangitis giant cell associated with haemolysis is documented. Ciclosporin promising all these diseases.We reviewed the records 12 patients treated our unit between 1987 2001. Eight had hepatitis, two hepatitis. Indications ciclosporin were failure (four patients) contraindications to/refusal steroids (eight patients). was administered five...

10.1046/j.1365-2036.2003.01754.x article EN Alimentary Pharmacology & Therapeutics 2004-01-01
Coming Soon ...